glp-1 indianapolis FDA has approved a new pill for weight loss Eli Lilly says experimental GLP-1

After the development of Zepbound and anticipated demand, the company expanded its manufacturing and quality control processes with distribution to retail and mail-order pharmacies

In the SURPASS-2 study, tirzepatide 15 mg resulted in a faster and greater decline in body weight ( 5.5 kg) compared to semaglutide 1.0 mg, more than doubling the proportion of patients achieving at least 10% weight loss (57% vs 24%) [3]

Regarding this study, Splenser noted that it offered reassurance that in patients 66 years and older, GLP1-RA therapy may not increase risk of depression. However, it is likely that there are also several other factors at play

Diabetes and anxiety in US adults: findings from the 2006 behavioral risk factor surveillance system

In addition to stimulating the GLP-1 receptor, tirzepatide also activates the GIP receptor